REG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan
05/10/2022 17:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221005:nRSE9360Ba&default-theme=true
RNS Number : 9360B Diaceutics PLC 05 October 2022
5 October 2022
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), a leading
diagnostic commercialisation company which provides data, analytics and
technology enabled services via its proprietary DXRX platform to the precision
medicine market, has been notified that on 28 September 2022, Global Shares
Trustees (UK) Limited and and Zedra Trust Company (Guernsey) Limited, the
trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have
purchased ordinary shares ("Shares") on behalf of Stefan McDonald, Susanne
Munksted, Jordan Clark, Julie Browne and Nick Roberts (PDMRs), in respect of
their purchase of Shares pursuant to the Company's UK and Global Share
Incentive Plan ("the SIP Schemes") for employees. These purchases will be made
each month until further notice.
In accordance with the SIP Schemes, the Company has matched these purchases
with a matched share award over an equivalent number of Shares purchased by
the employee, in the proportion of 1:1.
Enquiries:
Diaceutics PLC
Nick Roberts, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405 0205
Caroline Forde diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young
About Diaceutics
At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.
Diaceutics' data capability is one of the three key value drivers it has
integrated into its unique DXRX platform alongside its global Lab network and
product suite tailored for Precision testing.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Stefan McDonald
2 Reason for notification
a. Position/Status Chief Growth Officer and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
0.92 p 163
Matched share award:
Price(s) Volume(s)
0.92 p 163
e. Date of the transaction Share purchase and Matched Share award: 28 September 2022
f. Place of the transaction Share Purchase and Matched Share Award: AIM Market of the London Stock
Exchange
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Susanne Munksted
2 Reason for notification
a. Position/Status Chief Precision Medicine Officer and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Global Share Incentive Plan
("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
0.92 p 170
Conditional share award:
Price(s) Volume(s)
Nil 170
e. Date of the transaction Share purchase and Conditional share award: 28 September 2022
f. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange
Conditional share award: Off-Market
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Jordan Clark
2 Reason for notification
a. Position/Status Chief Commercial Officer and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
0.92 p 163
Matched share award:
Price(s) Volume(s)
0.92 p 163
e. Date of the transaction Share purchase and Matched Share award: 28 September 2022
f. Place of the transaction Share Purchase and Matched Share Award: AIM Market of the London Stock
Exchange
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Julie Browne
2 Reason for notification
a. Position/Status Chief Operations Officer and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
0.92 p 163
Matched share award:
Price(s) Volume(s)
0.92 p 163
e. Date of the transaction Share purchase and Matched Share award: 28 September 2022
f. Place of the transaction Share Purchase and Matched Share Award: AIM Market of the London Stock
Exchange
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Nick Roberts
2 Reason for notification
a. Position/Status Chief Finance Officer and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
0.92 p 163
Matched share award:
Price(s) Volume(s)
0.92 p 163
e. Date of the transaction Share purchase and Matched Share award: 28 September 2022
f. Place of the transaction Share Purchase and Matched Share Award: AIM Market of the London Stock
Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFSFFMIEESESSRecent news on Diaceutics
See all newsREG - Diaceutics PLC - Appointment of Amie Mc Neice as VP of Marketing
AnnouncementREG - Diaceutics PLC - Block Listing Return
AnnouncementREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan
AnnouncementREG - Diaceutics PLC - Director/PDMR/PCA Shareholding & TR1
AnnouncementRCS - Diaceutics PLC - Significant upgrade to Diaceutics' DXRX platform
Announcement